Inhibiteur de la DPP-4 ou des SGLT2 apres echec de la metformine seule dans le diabete de type 2.

[en] After failure of a monotherapy with metformin, dipeptidyl peptidase-4 inhibitors (gliptins) and sodium-glucose cotransporters type 2 (gliflozins) offer an alternative to the add-on of a sulphonylurea, especially in diabetic patients at risk of hypoglycaemia. The choice between a gliptin and a gliflozin may be guided by the individual patient characteristics : rather a gliptin in a patient without obesity or severe hyperglycaemia, in an elderly patient, with a frailty profile or with renal impairment; rather a gliflozin in an obese patient, with hypertension, hyperuricaemia, antecedents of cardiovascular disease (especially heart failure), without advanced renal insufficiency and with a low risk of urinary/genital infections or events linked to dehydration such as hypotension.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Paquot, Nicolas ; Université de Liège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques

Scheen, André ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Inhibiteur de la DPP-4 ou des SGLT2 apres echec de la metformine seule dans le diabete de type 2.

Alternative titles :

[en] DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes

Publication date :

2017

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Special issue title :

Thérapeutique

Volume :

Issue :

571

Pages :

1410-1415

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 September 2017

Statistics

Number of views

557 (6 by ULiège)

Number of downloads

753 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract 2016; 22: 84-113.
American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017;40:S1-S135.
Scheen AJ, Paquot N. Actualisation 2015 du traitement de lhyperglycémie dans le diabète de type 2. Rev Med Suisse 2015;11:1518-5.
Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225-36.
UKPDS group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS)Group. Lancet 1998;352: 854-65.
Scheen AJ. Utilisation des antidiabétiques oraux en cas dinsuffisance rénale. Rev Med Suisse 2012;8:1614-20.
Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother 2015;16:43-62.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-Transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.
Guthrie RM. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Postgrad Med 2015;127:463-79.
Scheen AJ. SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol 2013;1:168-70.
Scheen AJ, Paquot N. Le choix entre un inhibiteur de la DPP-4 et un inhibiteur des SGLT2 pour traiter le diabète de type 2. Rev Med Liege 2016;71:579-85.
Scheen AJ. Comment je traite .. Le choix entre un sulfamide hypoglycémiant et une gliptine pour traiter le diabète de type 2. Rev Med Liege 2014;69:476-84.
Scheen AJ. Comment je traite .. A propos du positionnement des inhibiteurs de la DPP-4 (gliptines) dans le traitement du diabete de type 2. Rev Med Liege 2015;70:593-9.
Van Gaal L, Scheen A. Weight management in type 2 diabetes: Current and emerging approaches to treatment. Diabetes Care 2015;38:1161-72.
Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): Focus on drug-drug interactions. Clin Pharmacokinet 2010;49:573-88.
Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 2015;14:505-24.
Paolisso G, Monami M, Marfella R, et al. Dipeptidyl peptidase-4 inhibitors in the elderly: More benefits or risks? Adv Ther 2012;29:218-33.
Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 2015;54:1-21.
Abdelmoneim AS, Eurich DT, Light PE, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obesity Metab 2015;17:523-32.
Scheen AJ. Gliptines, sécurité cardiovasculaire et insuffisance cardiaque : le point après létude TECOS. Rev Med Suisse 2015;11: 1518-25.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 2117-28.
Scheen AJ, Wallemacq C, Jandrain B, et al. Protection cardiovasculaire du patient diabétique de type 2 : dEMPAREG OUTCOME à LEADER. Rev Med Suisse 2016;12:1370-5.
Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-31.
Scheen AJ, Paquot N. Metabolic effects of SGLT2 inhibitors beyond increased glucosuria: A review of clinical evidence. Diabetes Metab 2014;40:S4-S11.
Scheen AJ. SGLT2 inhibitors: Benefit /risk balance. Curr Diabetes Rep 2016;16:92 27 Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium glucose cotransporter 2 (SGLT2) inhibition. Diabetes Care 2015;38:1730-5.
Scheen AJ. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 2016;121:204-14.
Schils R, Krzesinski JM. Hyperuricémie et risque potentiel de pathologie cardio-vasculaire et rénale. Rev Med Liege 2016;71:262-8.
Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2016;4:1004-16.
Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? Ann Endocrinol (Paris) 2013;74:515-22.
Nauck M. Incretin therapies: Highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obesity Metab 2016;18:203-16.
Nauck MA, Kahle M, Baranov O, et al. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes Obesity Metab 2017;19:200-7.
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37:1526-34.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975.
Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Clin Pharmacokinet 2015;54:691-708.
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-42.
Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: From rationale to clinical aspects. Expert Opin Drug Metab Toxicol 2016;12:1407-17.
Scheen AJ, Paquot N. Combinaison gliptine-gliflozine dans le traitement du diabète de type 2. Rev Med Suisse 2016;12:1384-8.
Dey J. SGLT2 inhibitor /DPP-4 inhibitor combination therapy-complementary mechanisms of action for management of type 2 diabetes mellitus. Postgrad Med 2017;129:409-20.
Scheen AJ. Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2017;13:583-92.
Garnock-Jones KP. Saxagliptin /dapagliflozin: A review in type 2 diabetes mellitus. Drugs 2017;77:319-30.
Triplitt C, Solis-Herrera C, Cersosimo E, et al. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2015;16:2819-33.
Aronson R. Single-pill combination therapy for type 2 diabetes mellitus: Linagliptin plus empagliflozin. Cur Med Res Opin 2015;31:901-11.